Elevance Health Q1 FY26 earnings call ELV

Elevance reported Q1 adjusted diluted EPS of $12.58, above its own expectations, and raised full-year 2026 adjusted EPS guidance to at least $26.75. Operating revenue totaled $49.5 billion, up 1.5% YoY, as higher premium yields were largely offset by lower health plan membership versus the prior year. The beat included roughly $1 per share of nonrecurring valuation adjustments within net investment income, which management explicitly excluded from the $25.75 revised 2026 baseline used to frame at-least-12% adjusted EPS growth in 2027. Of the ~$0.45 of core outperformance, about $0.30 was underlying business favorability and ~$0.15 was seasonality timing.

The consolidated benefit expense ratio was 86.8%, with medical costs modestly better than assumed. Management attributed roughly two-thirds of the operating outperformance to favorable claims experience and trend-management actions, and one-third to Individual ACA seasonality. A less severe flu-like season contributed about $0.10 of the benefit. Levers cited include earlier use of data to find outliers, utilization management, stronger payment integrity, and site-of-care optimization. Management stressed the guide does not rely on a friendlier trend environment and that actions will continue to gain traction through the year.

Medicaid performance was slightly favorable to expectations, benefiting from cost-management initiatives in behavioral health and specialty pharmacy, including rigorous clinical oversight of ABA therapy and predictive analytics for substance-use-disorder risk. Q1 trend was slightly ahead of expectations on favorable claims development, but underlying cost trend remains elevated at the high end of the mid-single-digit range while rates are coming in close to mid-single-digit — slightly below trend. Membership is expected to decline high single digits for the year, finishing toward the higher end of the range; management reiterated 2026 as the trough year and pointed to better rate alignment in 2027.

Medicare results were stronger than anticipated, reflecting 2026 portfolio actions including product repositioning and selective market exits, keeping the business on track for an operating margin of at least 2% in 2026. Management was encouraged that CMS addressed a portion of the funding challenges in the final 2027 rates and said it will remain disciplined in bid submissions, prioritizing plans that deliver long-term value.

Commercial Group developed as planned under the disciplined pricing outlined last quarter, with national account renewal near 99.3% and an almost-record 2027 pipeline supported by early wins and continued carrier consolidation. Carelon Rx delivered a strong 2026 ASO selling season including two marquee national wins and improved win rates in middle market and large group. In Individual ACA, membership grew sequentially with a pronounced shift toward bronze plans, driven partly by 2025 expansion states; the shift is a positive on a net-of-subsidy basis given higher benchmark silver premiums in 2026.

Carelon's Q1 operating gain declined modestly YoY on lower health plan membership and continued investment in risk-based capabilities, partly offset by improvement in specialty pharmacy and CareBridge. Management is combining CareBridge and Care at Home into a single risk-based solution, citing 20% reduction in hospital readmissions and more than 10% savings on post-acute care. Risk-based programs are being scaled using affiliated membership as a proving ground — oncology (started 2024, expanded to Medicare, Medicaid in 2H26), post-acute, and behavioral health for serious mental illness in Medicaid.

Elevance is investing more than $1 billion in digital and AI-enabled capabilities. Cited proof points include an AI-enabled virtual assistant used by 22 million commercial members, the Sydney personalized care-provider matching tool (500+ data points, used by more than 20% of members), and HealthOS supporting prior-authorization commitments with AI expected to reduce denials by more than ~70%. Over 60,000 associates have access to AI productivity tools. Management framed AI as embedded and scaling — reducing administrative expense and enabling earlier, more personalized clinical interventions — rather than pilots.

Following a February CMS notice on historical risk-adjustment data, Elevance recorded a $935 million accrual as its current best estimate of probable exposure, excluded from adjusted earnings. Management said the matter relates to historical payment disputes and interpretation of risk-adjustment policy, does not affect current operations or the outlook, and that CMS extended the compliance timeline to July 31; if the prescribed steps are completed, sanctions are expected not to go into effect. Separately, a $129 million business optimization charge was recorded for organizational simplification.